Spyre Therapeutics Says Both Doses Of SPY072 Met Statistical Significance On One Or More Endpoints In Phase 2 SKYWAY Rheumatoid Arthritis Sub-Study; Says Effect Did Not Meet Its Bar To Prioritize Monotherapy Development In RA

뉴스 본문을 불러오고 있어요.

Spyre Therapeutics Says Both Doses Of SPY072 Met Statistical Significance On One Or More Endpoints In Phase 2 SKYWAY Rheumatoid Arthritis Sub-Study; Says Effect Did Not Meet Its Bar To Prioritize Monotherapy Development In RA | 웨이프 WAPE

Spyre Therapeutics Says Both Doses Of SPY072 Met Statistical Significance On One Or More Endpoints In Phase 2 SKYWAY Rheumatoid Arthritis Sub-Study; Says Effect Did Not Meet Its Bar To Prioritize Monotherapy Development In RA

기사 요약

관련 종목

댓글 —